1. Home
  2. Products
  3. Customized ADCs
  4. CD22
  5. Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC (CAT#: ADC-W-461)

This ADC product is comprised of an Anti-CD22 antibody (clone G5/44) conjugated via a AcBut linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, CalichDMH binds to DNA, causes DNA damage.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • G5/44
  • Similar to
  • inotuzumab ozogamicin
  • Name
  • CD22
  • Alternative Names
  • CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
  • Target Entrez Gene ID
  • 933
  • Overview
  • CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
  • Overview
  • Humanized Anti-CD22 Antibody, clone # G5/44
  • Generic name
  • inotuzumab
  • Clone #
  • G5/44
  • Species Reactivity
  • Human
  • Name
  • AcBut (4-(4-acetylphenoxy)butanoic acid)
  • Description
  • Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
  • Name
  • CalichDMH
  • Description
  • Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-461. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2523 Anti-CD22 (Inotuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2536 Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2526 Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2533 Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2524 Anti-CD22 (Inotuzumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
CAT# Product Name Linker Payload
ADC-W-464 Anti-CD33 (clone hP67.6)-AcBut-Calicheamicin ADC AcBut (4-(4-acetylphenoxy)butanoic acid) Calicheamicin
CAT# Product Name Linker Payload
ADC-W-459 Anti-FUT3 (clone hu3S193)-AcBut-CalichDMH ADC  AcBut [-(4' acetyl phenoxy) butanoic acid] CalichDMH

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.